New Delivery Tech Targets siRNA to Breast Cancer Cells to Suppress HER2-Positive Tumor Growth | GenomeWeb

An international team of researchers this month reported on the development of a targeted delivery system capable of shuttling siRNAs into breast cancer cells, resulting in suppression of HER2-positive tumor growth and metastasis with no evident toxicity.

According to Harvard Medical School's Judy Lieberman, who is one of the paper's authors and a co-developer of the technology, the results are highly promising but further development work will likely need to be conducted in collaboration with an industry partner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.